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Predictive Value of Microvolt T-Wave
Alternans in Patients With Left Ventricular Dysfunction
Daniel J. Cantillon, MD, Kenneth M. Stein, MD, FACC, Steven M. Markowitz, MD, FACC,
Suneet Mittal, MD, FACC, Bindi K. Shah, MD, FACC, Daniel P. Morin, MD, MPH,
Eran S. Zacks, MD, Matthew Janik, MD, Shaun Ageno, MD, Andreas C. Mauer, MD,
Bruce B. Lerman, MD, FACC, Sei Iwai, MD, FACC
New York, New York
Objectives The purpose of this study was to prospectively evaluate the utility of microvolt T-wave alternans (TWA) in predict-
ing arrhythmia-free survival and total mortality in patients with left ventricular (LV) dysfunction.
Background Microvolt TWA has been proposed as a useful tool in identifying patients unlikely to benefit from prophylaxis
with implantable cardioverter-defibrillator (ICD) prophylaxis.
Methods We evaluated 286 patients with an LV ejection fraction 35% who underwent TWA and electrophysiologic test-
ing (EPS) owing to nonsustained ventricular tachycardia and/or syncope. Positive and indeterminate TWA results
were grouped as non-negative. The primary end point was arrhythmia-free survival; the secondary end point was
all-cause mortality.
Results Patients were followed for a mean of 38  11 months. There was no significant difference between the TWA-
negative (n  90; 31%) and non-negative (n  196; 69%) groups with respect to ICD implant rates (54% vs.
64%, respectively; p  0.95) or etiology of cardiomyopathy (ischemic: 73% vs. 76%; p  0.71). The Kaplan-
Meier curves demonstrated improved arrhythmia-free survival in TWA-negative patients (81% vs. 66% at 2 years;
p  0.001), including in both ischemic (79% vs. 64% at 2 years; p  0.004) and nonischemic (88% vs. 71% at 2
years; p  0.015) subgroups. Total mortality was lower in the TWA-negative group (10% vs. 18% at 2 years; p 
0.04). The negative predictive value of TWA for (2-year) total mortality was 90%, and 83% for EPS.
Conclusion Microvolt TWA predicts arrhythmia-free survival among patients with LV dysfunction. However, the event rate in
the TWA-negative group suggests that TWA may not be capable of identifying a sufficiently low-risk subset in
this population to obviate the need for ICD implantation. (J Am Coll Cardiol 2007;50:166–73) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.069M
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audden cardiac death is responsible for over 400,000 deaths in
he U.S. annually and is mostly attributable to ventricular
rrhythmias (1). Within the past decade, microvolt T-wave
lternans (TWA) testing has emerged as a potential means of
isk-stratifying patients with respect to sudden cardiac death
2–5). Although large clinical trials such as the SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial) (6) and the
rom the Department of Medicine, Division of Cardiology, Cornell University
edical Center, New York, New York. Supported in part by grants from the National
nstitutes of Health (RO1 HL-56139), the American Heart Association, Grant-in-
id (New York City Affiliate), the Maurice and Corinne Greenberg Arrhythmia
esearch Grant, the Raymond and Beverly Sackler Foundation, and the Michael
olk Foundation. Drs. Stein, Mittal, Shah, Lerman, and Iwai have received
onoraria from Guidant (now Boston Scientific) and Medtronic. Dr. Stein has
eceived honoraria from Cambridge Heart.
Manuscript received December 29, 2006; revised manuscript received February 5,
V007, accepted February 13, 2007.ADIT-II (Multicenter Automatic Defibrillator Implanta-
ion Trial II) (7) have demonstrated a survival benefit with
rophylactic implantable cardioverter-defibrillator (ICD) im-
lantation in patients with left ventricular (LV) dysfunction,
he substantial cost of ICD implantation and relatively high
umber that need to be treated to save one life suggest that
urther risk stratification could be useful (8–10).
See page 174
Electrophysiologic studies (EPS) have been used in the
isk stratification for sudden death. This is partially based on
he MADIT study (11) of postmyocardial infarction pa-
ients with reduced LV function and nonsustained ventric-
lar tachycardia (VT), demonstrating a survival benefit
mong ICD recipients who were inducible for sustained
T. However, arrhythmic event rates were sufficiently high
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July 10, 2007:166–73 T-Wave Alternans in LV Dysfunctionmong the noninducible patients in the MUSTT (Multi-
enter Unsustained Tachycardia Trial) registry (12) to raise
oncerns about its negative predictive value in this patient
opulation. Furthermore, the role of EPS in relation to
icrovolt TWA testing, as well as their relative effectiveness
s screening tools remains unclear. There is a paucity of
rospective data comparing the 2 concomitantly among
atients with LV dysfunction.
The purpose of the present study was to better define the
rognostic value of microvolt TWA among patients with
eft ventricular dysfunction to determine whether TWA can
dentify sufficiently low-risk patients unlikely to benefit
rom a prophylactic ICD implantation. We also sought to
ompare TWA with EPS in their ability to risk-stratify this
atient population. Therefore, we designed a prospective
bservational study to evaluate the utility of TWA in
redicting arrhythmia-free survival in patients with LV
ysfunction (LV ejection fraction [EF] 35%) among
atients who underwent both EPS and TWA for sudden
ardiac death risk-stratification.
ethods
tudy population and design. We prospectively screened
50 patients who underwent simultaneous EPS and TWA
or evaluation of nonsustained VT and/or syncope, between
anuary 1, 2001, and December 31, 2003, at our institution.
atients were eligible if they were at least 18 years old, gave
nformed consent, and were in sinus rhythm at the time of
valuation. Patients with LV dysfunction as defined by
VEF 35% were included in the study, regardless of
tiology of cardiomyopathy. Patients with a history of
udden cardiac death or sustained ventricular arrhythmias
ere excluded. The primary composite end point,
rrhythmia-free survival, was defined as freedom from death
r sustained ventricular arrhythmias (VT or ventricular
brillation [VF]). Ventricular tachycardia was defined as
ustained if the episode lasted for 30 s, or required
ardioversion or appropriate ICD shock. The secondary end
oint was all-cause mortality. The study was approved by
ur Institutional Review Board.
ardiomyopathy classification. Cardiomyopathy was de-
ermined to be ischemic in origin if any of the following
riteria were met: 1) stenosis of a major epicardial coronary
rtery of 70%; 2) history of coronary artery bypass graft
urgery; 3) history of percutaneous cardiovascular revascu-
arization; or 4) documented prior myocardial infarction. All
ther patients were deemed to have cardiomyopathy due to
nonischemic etiology.
lectrophysiologic study. After giving informed written
onsent, patients underwent electrophysiologic evaluation
fter an overnight fast. Patients were locally anesthetized
sing 0.25% bupivacaine and minimally sedated with intra-
enous midazolam, morphine, and/or fentanyl. Quadripolar
-F catheters were advanced from the femoral veins to the
igh right atrium, His bundle position, and right ventricular wpex and/or outflow tract. Bipo-
ar intracardiac electrograms
ere filtered at 30 to 500 Hz.
he stimulation protocol in-
luded burst atrial and ventricu-
ar pacing and the introduction
f single atrial and up to triple
entricular extrastimuli from 1 or
right ventricular sites. Stimuli
ere delivered as rectangular
ulses of 2-ms duration at 4
imes diastolic threshold. A pos-
tive EPS was defined as sus-
ained monomorphic VT induc-
ble with up to triple extrastimuli
r polymorphic VT or VF induc-
ble with up to double extra-
timuli in the basal state.
icrovolt TWA testing.
valuation of microvolt T-wave
lternans was performed during atrial pacing at the time of
lectrophysiologic study, as previously validated (13). Care-
ul skin preparation included mild abrasion and placement
f high-resolution electrodes (High-Res, Cambridge Heart,
edford, Massachusetts). Electrocardiographic leads were
laced in the standard 12-lead and orthogonal X, Y, and Z
onfigurations. The protocol involved measurement during
ight atrial pacing at cycle length of 550 ms for 5 min. The
WA was analyzed using either the CH2000 or the
earTwave system (Cambridge Heart). A positive test was
efined as TWA sustained for 1 min with alternans
oltage (Valt) 1.9 V and TWA ratio 3.0, according to
reviously published criteria (14). A negative test was
efined as the absence of significant TWA (i.e., 1.9 V)
uring atrial pacing. Causes of an indeterminate test in-
luded excessive (ventricular or atrial) ectopy, atrioventric-
lar Wenckebach, and excessive artifact due to noise.
ositive and indeterminate TWA test results were grouped
s non-negative according to convention from earlier studies
14). Recent data in patients with LV dysfunction have
ndicated that patients with indeterminate and positive
WA tests have a similar risk of death or sustained
entricular arrhythmias (15).
linical follow-up. Patients were followed by routine
linic visits for device interrogation at scheduled intervals,
tandardized telephone interviews, and institutional hospital
dmissions tracked using electronic medical records. When
ecessary to assess end points, detailed records from outside
nstitutions and physicians were obtained with patient
onsent given separately during the follow-up period. All
eath events were independently verified against the Social
ecurity Death Index for precise measurement of survival
ime from the time of evaluation. The minimum event-free
ollow-up time interval required for inclusion was defined as
12 months, and those who did not meet this standard
Abbreviations
and Acronyms
EF  ejection fraction
EPS  electrophysiology
study
ICD  implantable
cardioverter-defibrillator
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
NPV  negative predictive
value
NYHA  New York Heart
Association
TWA  T-wave alternans
VT  ventricular
tachycardiaere considered lost to follow-up.
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T-Wave Alternans in LV Dysfunction July 10, 2007:166–73tatistics. Continuous variables were expressed as mean
standard deviation, and comparisons between groups
ere made using the independent samples t test. Cate-
oric variables, expressed as numbers and percentages,
ere compared using chi-square analysis. Kappa test was
sed to measure agreement between EPS and TWA
esults. Kaplan-Meier curves were constructed to describe
he arrhythmia-free survival and total mortality experi-
nce for TWA negative and non-negative patients, in-
luding the presence or absence of ischemic heart disease.
he log-rank test was applied for statistical significance.
he Cox proportional hazards model was applied to
ssess TWA results and the primary end point of
rrhythmia-free survival, as expressed by a hazard ratio
HR) with a 95% confidence interval (CI). A correspond-
ng analysis was performed using Cox regression to
nvestigate potential confounding variables for interac-
ion with TWA results. Candidate variables included age,
ender, LV function, New York Heart Association
NYHA) functional classification, QRS duration, use of
eta-blockers, cardiomyopathy etiology, EPS result, ICD
mplantation, and TWA testing. These variables were
onsidered individually and collectively, with p values
ased on the Wald test from the Cox models. For all
ests, p values of 0.05 were considered to be significant.
ata analysis was performed using SPSS for Windows
10.1 (SPSS Inc., Chicago, Illinois).
Baseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Characteristic
All
(n  286)
Age, yrs 65  11
Male gender 224 (78%)
LVEF, % 26  7
Ischemic cardiomyopathy 214 (75%)
QRS duration, ms
110 145 (54%)
110–120 67 (25%)
120 74 (28%)
NYHA functional classification
I 33 (12%)
II 135 (47%)
III 105 (37%)
IV 13 (5%)
Medications
Beta-blocker 237 (83%)
ACE inhibitor/ARB 207 (72%)
Statin 133 (47%)
Amiodarone 14 (5%)
Reason for evaluation
Syncope 23 (8%)
Nonsustained VT 240 (84%)
Both 23 (8%)
ICD implant after EPS 174 (61%)ACE  angiotension-converting enzyme; ARB  angiotensin receptor block
defribrillator; LVEF  left ventricular ejection fraction; NYHA  New York Hearesults
uring the enrollment period, 344 patients met the criteria
or LV dysfunction (EF 35%), and 36 of these were
ubsequently excluded based on a history of sudden cardiac
eath or sustained ventricular arrhythmias. Among the 308
emaining eligible patients, 20 were lost to follow-up and 2
ubsequently withdrew consent during the follow-up period.
verall, 286 of the 308 eligible patients (93%) were fol-
owed up for a mean of 38  11 months.
The baseline clinical characteristics of the 286 patients
re detailed in Table 1. The mean age was 65  11 years,
nd 224 (78%) were male. Two hundred fourteen patients
75%) had an ischemic cardiomyopathy, and 72 (25%) had
nonischemic cardiomyopathy. The average LVEF of the
roup was 26  7%. One hundred forty-five patients (51%)
ad a normal QRS, 67 (23%) had evidence of intraventric-
lar conduction delay (QRS 110 to 120 ms), and 74 (26%)
ad bundle branch block (QRS 120 ms). The NYHA
ongestive heart failure classification distribution at the time
f the study was: 33 (12%) were class I, 135 (47%) class II,
05 (37%) class III, and 13 (5%) class IV. Two hundred
hirty-seven patients (83%) were treated with beta-blockers,
07 (72%) with either an angiotensin-converting enzyme
nhibitor or angiotensin receptor blocker, 133 (47%) with a
tatin, and 14 (5%) with amiodarone. Two hundred forty
atients (84%) were referred for nonsustained VT, 23 (8%)
A Negative
(n  90)
TWA Positive or
Indeterminate
(n  196) p Value
65  11 66  12 0.73
70 (78%) 154 (79%) 0.99
27  7 26  7 0.83
66 (73%) 148 (76%) 0.71
0.17
53 (59%) 92 (47%)
18 (20%) 49 (25%)
19 (21%) 55 (28%)
0.38
8 (9%) 25 (13%)
47 (52%) 88 (45%)
33 (37%) 72 (37%)
2 (2%) 11 (6%)
71 (79%) 166 (85%) 0.91
61 (68%) 146 (75%) 0.91
41 (46%) 92 (47%) 0.90
2 (2%) 12 (6%) 0.24
0.56
9 (10%) 14 (7%)
76 (84%) 164 (84%)
5 (6%) 18 (9%)
49 (54%) 125 (64%) 0.95TWer; EPS  electrophysiology study; ICD  implantable cardioverter-
t Association; TWA  T-wave alternans; VT  ventricular tachycardia.
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July 10, 2007:166–73 T-Wave Alternans in LV Dysfunctionor syncope, and 23 (8%) for both syncope and nonsustained
T.
The TWA testing was performed at the time of the EPS.
he TWA was negative in 90 patients (31%) and non-
egative in 196 (69%). The non-negative group included
21 positive (42%) and 75 indeterminate (26%) results.
nly 5 of the indeterminate cases were due to noise (7%),
ith the remainder due to atrioventricular Wenckebach (23
30%]) or excessive atrial or ventricular ectopy (47 [63%]).
The TWA-negative and –non-negative patients were
omparable with respect to age, LVEF, prevalence of
schemic heart disease, NYHA functional classification, and
tandard cardiac medications (Table 1).
Overall, 174 patients (61%) underwent ICD implanta-
ion. There was no significant difference between the
WA-negative and –non-negative groups with respect to
ates of subsequent ICD implantation (n  49 [54%] vs.
25 [64%], respectively; p  0.95).
orrelation between TWA and EPS. The EPS was
ositive in 115 patients (40%). Of those patients, 86 (75%)
ad a non-negative TWA result. In the 171 patients who
ere noninducible for VT at EPS, 61 (36%) had a negative
WA result (Table 2). Conversely, of the 90 patients with
negative TWA result, 61 (68%) had a negative EPS. In
he non-negative TWA group (196 patients), 86 (44%) had
positive EPS. Therefore, 139 patients (49%) had discor-
ant results with respect to EPS and TWA. In a bivariate
nalysis, there was no statistically significant agreement
etween EPS and TWA results (kappa value 0.09).
When looking at the agreement between EPS and TWA
n patients with ischemic and nonischemic cardiomyopathy
eparately, there was still no strong agreement in either
roup, although the patients with ischemic cardiomyopathy
ad a slightly better concordance, as would be expected. Of
he 214 ischemic cardiomyopathy patients, 111 had a
ositive EPS result (84 [76%] of whom had a non-negative
WA result) and 103 had a negative EPS (39 [38%] of
greement Between TWA and EPS Results
Table 2 Agreement Between TWA and EPS Results
TWA Negative
(n  90)
TWA Non-Negative
(n  196)
All patients (kappa score 0.9)
Total 90 196
EPS positive (n  115) 29 86
EPS negative (n  171) 61 110
Ischemic cardiomyopathy patients (kappa score 0.14)
Total 66 148
EPS positive (n  111) 27 84
EPS negative (n  103) 39 64
Nonischemic cardiomyopathy patients (kappa score 0.03)
Total 24 48
EPS positive (n  16) 6 10
EPS negative (n  56) 18 38
PS is defined as positive only if inducible without catecholamine infusion.
Abbreviations as in Table 1.hom had a negative TWA) (Table 2). In the 72 nonisch-mic cardiomyopathy patients, 16 had a positive EPS (10
63%] of whom also had a non-negative TWA), and 56 had
negative EPS (18 [32%] of whom had a negative TWA)
Table 2). Kappa values were 0.14 for the ischemic popu-
ation and 0.03 for the nonischemic population.
urvival data. Kaplan-Meier survival analysis demon-
trated improved arrhythmia-free survival in TWA-negative
atients compared with non-negative patients (81% vs. 66%
t 2 years, respectively; p  0.0001) (Fig. 1). Of note,
WA-positive and -indeterminate patients had similar
ates of arrhythmia-free survival (66% vs. 65%, respectively;
ata not shown). All-cause mortality was also lower in the
WA-negative group than in the TWA–non-negative
roup (10% vs. 17% at 2 years, respectively; p  0.04)
Fig. 2).
In univariate analysis, TWA testing was a strong predic-
or of the primary end point of arrhythmia-free survival
HR 2.33, 95% CI 1.44 to 3.67; p 0.01). In contrast, EPS
as not found to be a statistically significant predictor of
rrhythmia-free survival (HR 1.27, 95% CI 0.88 to 1.83; p
0.21). Multivariate analysis was also performed, and
ncluded age, gender, QRS duration, LVEF, NYHA con-
estive heart failure class, cardiomyopathy etiology (isch-
mic vs. nonischemic), and subsequent ICD implantation,
s detailed in Table 3. There were no significant interactions
etween any of these variables. The TWA testing remained
significant predictor of the primary end point when
djusted for the other variables (multivariate HR 2.37, 95%
I 1.49 to 3.81; p  0.01).
Figure 1 Kaplan-Meier Survival Curves
for Arrhythmia-Free Survival
Stratified by T-wave alternans (TWA) testing result.
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CI  confidence interval; HR  hazard ratio; other abbreviations as in Tabl
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T-Wave Alternans in LV Dysfunction July 10, 2007:166–73The arrhythmia-free survival benefit for TWA-negative
ersus –non-negative patients persisted when evaluated
eparately in the ischemic cardiomyopathy (79% vs. 64% at
years, respectively; p  0.004) and nonischemic cardio-
yopathy (88% vs. 71% at 2 years, respectively; p  0.015)
atient subgroups (Figs. 3A and 3B).
When stratified by both EPS and TWA results, there
as a significant difference in 2-year event rates for
rrhythmia-free survival (p  0.0006) (Fig. 4); i.e., the
ddition of 1 test to the other added to the negative
redictive value. The 2-year event rates were as follows: 1)
PS and TWA negative: 15% (n  61); 2) EPS positive
nd TWA negative: 28% (n  29); 3) EPS negative and
WA–non-negative: 35% (n  110); and 4) EPS positive
nd TWA–non-negative: 33% (n  86).
iscussion
he present results demonstrate that, compared with elec-
rophysiologic evaluation, microvolt TWA testing is a more
ffective predictor of arrhythmia-free survival and all-cause
ortality in patients with nonsustained VT and/or syncope.
Although our findings are concordant with earlier obser-
ational studies (16–19) that evaluated the utility of TWA,
d Ratios
%) Univariate HR (95% CI) p Value
1.07 (0.73–1.57) 0.71
0.64 (0.38–1.08) 0.09
1.05 (0.71–1.56) 0.81
1.00 (0.62–1.62) 0.16
1.39 (0.91–2.10) 0.13
0.79 (0.46–1.15) 0.17
1.04 (0.66–1.67) 0.85
1.27 (0.88–1.83) 0.20
2.33 (1.44–3.67) 0.01
; p  0.01) for TWA result and primary end point of arrhythmia-free
lysis using Cox models. None of the other interactions examined wereFigure 2 Kaplan-Meier Survival Curves for All-Cause Mortality
Stratified by T-wave alternans (TWA) testing result.2-Year Event Rates and Univariate Hazard Ratios
Table 3 2-Year Event Rates and Univariate Hazar
Variable* n 2-Year Events (
Age
65 yrs 155 31.3
65 yrs 131 29.3
Gender
Female 62 24.7
Male 224 30.9
LVEF
30% 134 30.5
30% 152 29.5
QRS duration (ms)
120 74 35.0
120 212 27.4
NYHA functional class
III or greater 118 35.0
II or less 168 27.8
Beta-blockers
Yes 237 27.5
No 49 39.9
Cardiomyopathy
Ischemic 214 30.9
Nonischemic 72 20.4
EPS
Positive 115 40.2
Negative 171 59.8
Microvolt TWA*
Non-negative 196 34.3
Negative 90 19.1
All p values are based on Wald test. *Adjusted HR 2.37 (95% CI 1.49 to 3.81
survival after adjustment for the other table variables listed in multivariate anae 1.
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July 10, 2007:166–73 T-Wave Alternans in LV Dysfunctionhe present results demonstrate substantially higher event
ates in the TWA-negative group. Using 1-year negative
redictive value (NPV) for arrhythmia-free survival as a
ommon end point for comparison, the present study
emonstrated an NPV for TWA of 85%, compared with
4% in a recent series of patients with cardiomyopathy and
F 40%, (16) and with 92% in a series of patients with
schemic cardiomyopathy and EF 35% (17). In contrast
Figure 3 Kaplan-Meier Survival Curves
for Arrhythmia-Free Survival
Stratified by T-wave alternans (TWA) testing result and subgrouped by etiology
of cardiomyopathy: (A) ischemic cardiomyopathy patients; (B) nonischemic
cardiomyopathy patients.ith those series, the present patients were referred forvaluation specifically based on the presence of nonsustained
T and/or syncope, thus suggesting a potentially higher-
isk patient population, resulting in a higher rate of clinical
vents. In fact, 16% of our patients were evaluated for
yncope, one-half of whom also had nonsustained VT.
urthermore, both of the earlier studies excluded NYHA
unctional class IV patients, who were not excluded from
he present series (although they comprised a small minor-
ty), to assess the utility of TWA testing across the broad
pectrum of patients with congestive heart failure. The
ombination of these inclusion criteria may have resulted in
higher arrhythmia risk in the present group than in the
reviously studied low-risk primary prevention cohorts.
In the present study, EPS failed to predict the primary
nd point of arrhythmia-free survival, whereas TWA testing
as a strong predictor in both univariate and multivariate
nalyses. The superiority of TWA testing in this population
s likely due at least in part to the low inducibility rates
uring EPS of nonischemic cardiomyopathy patients. In
ddition, this is consistent with earlier data, which has
emonstrated the suboptimal negative predictive value of
PS. In the MUSTT registry, for example, patients with a
egative EPS still had 2-year rates of death of 21% and of
ardiac arrest or arrhythmic death of 12% (12). In the
resent series, subgroup analysis of the ischemic and non-
schemic patients demonstrated that TWA testing appears
o be robust in both cohorts.
Figure 4 Kaplan-Meier Survival Curves
for Arrhythmia-Free Survival
Stratified according to both electrophysiology study (EPS) and T-wave alternans
(TWA) results. EPS ()  EPS negative for inducible sustained ventricular
tachycardia (VT); EPS ()  EPS positive for inducible sustained VT; TWA ()
 TWA negative; TWA (/I)  TWA positive or indeterminate (non-negative).
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T-Wave Alternans in LV Dysfunction July 10, 2007:166–73iscordance between TWA and EPS. Our results also
ighlight the fact that, although TWA and EPS can both
e used to potentially risk-stratify patients for sudden
ardiac death, they identify different patient population sets.
lmost one-half of the present patients had discordant
esults with respect to TWA and EPS (i.e., non-negative
WA but negative EPS or negative TWA but positive
PS). However, it is important to highlight the fact that
aving both a negative TWA and negative EPS was
ssociated with a favorable 2-year NPV for freedom from
eath or sustained ventricular arrhythmia (85%), which was
etter than with either test alone (Fig. 4).
mplications for ICD implantation. Over 90% of the
atients in the present series would have met current criteria
or ICD implantation (with or without cardiac resynchro-
ization therapy). An important finding in this series is the
-year rate of 19% for the primary end point (of death or
ustained ventricular arrhythmias) among the TWA-
egative patients. This suggests that the TWA test alone
ay not be capable of identifying a sufficiently low-risk
ubset in this particular population to obviate the need for
CD implantation. The addition of another test, such as
PS in the present study, may improve the (combined)
PV sufficiently to stay below the threshold for ICD
mplantation. This approach also appears promising based
n the results of a published study examining patients with
hronic ischemic heart disease (20). The NPV of a test is
ependent on the pretest probability for a particular event.
n the present study, it is possible that the inclusion criteria
nonsustained VT and/or syncope along with significant LV
ysfunction) created a relatively high-risk cohort for ven-
ricular arrhythmias. Further prospective randomized stud-
es will be needed to evaluate whether the NPV of TWA
ould be sufficiently high in patients of the population
ncluded in our study as well as in a group without certain
otentially high-risk clinical markers (e.g., syncope or non-
ustained VT, different degrees of LV dysfunction) to
liminate the need for ICD implant. Any future algorithm
or ICD implantation using the results of TWA testing
erits evaluation in a randomized prospective clinical trial.
tudy limitations. This was an observational study rather
han a randomized controlled trial. As such, ICD implan-
ation was at the discretion of the electrophysiologist, and
as not randomized. However, previous TWA studies have
lso been observational, and withholding ICD therapy to
atients who meet current implant indications would be
roblematic. To mitigate the effect of this, we reported
rrhythmia-free survival as well as all-cause mortality. Of
ote, ICD implant rates were not significantly different
etween TWA-negative and –non-negative groups.
Also, the present study was performed using an atrial
acing protocol. Comparisons with earlier studies using a
readmill TWA protocol should be made with caution.
ifferences in autonomic tone, incidence of excessive arti-
act leading to an indeterminate result, and the ability to
each and maintain a sufficient heart rate might differ
1etween the 2 protocols. One published series suggests that
xercise testing might be superior for the risk stratification
f patients with ischemic LV dysfunction (21). However, in
hat study the selection of exercise vs. pacing T-wave
lternans evaluation was not randomized, and episodes of
T treated with antitachycardia pacing were included in the
nd point. Furthermore, although the authors found that
xercise TWA (but not pacing TWA) was a significant
redictor of events, the NPVs of the 2 modalities were
lmost identical.
onclusions
icrovolt TWA predicts arrhythmia-free survival for pa-
ients with LV dysfunction (EF 35%) who present with
onsustained VT and/or syncope. Furthermore, it appears
o be a robust predictor among patients with both ischemic
nd nonischemic cardiomyopathy across a broad spectrum
f clinical heart failure. In patients with LV dysfunction, it
utperforms EPS in predicting arrhythmia-free survival.
owever, in this population, the relatively high clinical
vent rate in the TWA-negative group suggests that TWA
esting alone may not be capable of identifying a sufficiently
ow-risk subset to obviate the need for ICD implantation in
atients with cardiomyopathy and nonsustained VT and/or
yncope. The addition of another risk-stratifying modality,
uch as EPS, may allow for a sufficiently high NPV for
rrhythmia-free survival. (18,19).
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